You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Tertiary Prevention of Cervical Cancer

DIVINE, LAURA M. MD*; HUH, WARNER K. MD

Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0000000000000020
Secondary Prevention of Cervical Cancer
Abstract

Human pappilomavirus (HPV) has been recognized as the most common sexually transmitted disease in the world and over 100 different HPV types have been identified. Persistent HPV infection has been closely linked to the development of invasive cervical cancer. Although surgical and ablative therapies have been the mainstay of treatment, vaccination against the main oncogenic type of HPV is a reasonable preventive strategy for HPV-induced cervical cancer.

Author Information

*Department of Obstetrics and Gynecology

Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama

W.K.H. has received a consulting fee or honoraria from Merck; received fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like from Inovio; and serves as a consultant for Intuitive and Novadaq. The remaining author declares that there is nothing to disclose.

Correspondence: Warner K. Huh, MD, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 1700 6th Avenue South, Suite 10250 Birmingham, AL 35233. E-mail: warner.huh@ccc.uab.edu

© 2014 by Lippincott Williams & Wilkins.